Once-daily combination tenofofovir disoproxil fumarate (TDF) and emtricitabine (FTC) has received Food and Drug Administration (FDA) approval for use in pre-exposure prophylaxis (PrEP) against Human Immunodeficiency Virus (HIV) infection in high-risk individuals. In clinical trials, FTC/TDF has been shown to reduce the risk of HIV acquisition by 62 percent in sexually active heterosexual men and women. Similarly, use of FTC/TDF demonstrated a 44 percent reduction in HIV infection within the men who have sex with men population.7 When used compliantly and in conjunction with safe sex practices, it appears that FTC/TDF can play an important role in reducing the impact and incidence of HIV infection.
Steele J, Blum E, Steinbrunner A, Long L, Roecker AM. Truvada® Recommended by FDA Committee for Pre-exposure Prophylaxis in High-Risk HIV-Negative Individuals. PAW Review. 2013 Jan 01; 4(1):Article 5 21-23 . Available from: https://digitalcommons.onu.edu/paw_review/vol4/iss1/5.